INTRODUCTION {#s1}
============

Glioma is the most common and the worst prognosis on primary central nervous system (CNS) tumors, making up approximately 30 % of all brain and CNS tumors and 80 % of all malignant brain tumors \[[@R1], [@R2]\]. However, the etiology of glioma is largely unknown. The radiation exposure and certain genetic syndromes are well-defined risk factors for malignant glioma \[[@R3]\]. The base excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR), and double strand break repair (DSBR) are the four major DNA repair pathways \[[@R4]\]. X-ray repair cross-complementing group 1 (XRCC1) gene, which is located on chromosome 19q 13.2--13.3 with a length of 33 kilobases, is one of the DNA repair genes encoding a scaffolding protein that participates in BER pathway \[[@R5], [@R6]\]. There are more than 300 validated single nucleotide polymorphisms (SNPs) in the XRCC1 gene in the dbSNP database; thereinto, Arg399Gln (rs25487), Arg280His (rs25489), and Arg194Trp (rs1799782) are the three extensively studied polymorphisms.

From 2012 to 2016, there are 14 meta-analyses \[[@R7]--[@R20]\] published to estimate the association between XRCC1 Arg194Trp polymorphism and glioma risk, but the results are contradictory ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). Hence, it is still unclear whether XRCC1 Arg194Trp polymorphism is associated with risk of glioma. In 2014, Adel Fahmideh et al \[[@R21]\] conducted a systematic review and meta-analysis to investigate the association between DNA repair gene polymorphisms (ERCC1 rs3212986, ERCC2/XPD rs13181, MGMT rs12917, PARP1 rs1136410, and XRCC1 rs25487) and risk of glioma. Obviously, XRCC1 rs1799782 polymorphism is not included. Moreover, there are many relevant studies which are published after the previous 14 meta-analyses and also yield inconsistent results. Therefore, we performed this updated and cumulative meta-analysis \[[@R22], [@R23]\] to explore the more precise association between Arg194Trp polymorphism and glioma risk. Subgroup analyses were also performed according to Caucasian and Asian populations to investigate ethnicity-specific effects; the subgroup analyses based on the source of controls and the HWE for controls were conducted as well.

RESULTS {#s2}
=======

Study selection and characteristics {#s2_1}
-----------------------------------

The primary search yielded 208 potentially related publications and finally 16 case-control studies involving 7011 patients and 9519 healthy controls were included \[[@R24]--[@R39]\]. Figure [1](#F1){ref-type="fig"} shows the study selection process. Of these studies, five dealt with probands of Caucasian origin \[[@R24]--[@R27], [@R30]\] and eleven referred to Asian origin \[[@R28], [@R29], [@R31]--[@R39]\]; five studies were out of Hardy Weinberg Equilibrium (HWE) \[[@R28], [@R30], [@R31], [@R34], [@R37]\]. Table [1](#T1){ref-type="table"} lists the main characteristics of identified studies.

![Flow chart from identification of eligible studies to final inclusion](oncotarget-08-21599-g001){#F1}

###### Characteristics of included studies in the meta-analysis

  References           Country (Ethnicity)            Case   Source of control   Control   Genotyping method   HWE                                          
  -------------------- ------------------------------ ------ ------------------- --------- ------------------- ------- ------ ------ ----- ---- ----------- -----
  Liu 2007             China (Asian)                  756    371                 308       77                  Mixed   754    375    305   74   TaqMan      Yes
  Kiuru 2008           Europeancountries(Caucasian)   700    626                 71        3                   PB      1556   1377   177   2    PCR-RFLP    Yes
  Liu 2009             USA (Caucasian)                210    180                 29        1                   PB      365    310    52    3    MassARRAY   Yes
  Mckean-Cowdin 2009   USA (Caucasian)                1022   842                 177       3                   Mixed   2022   1664   352   6    TaqMan      Yes
  Rajaraman 2010       USA (Caucasian)                342    304                 38        0                   HB      468    394    73    1    TaqMan      Yes
  Hu 2011              China (Asian)                  127    71                  38        18                  HB      249    163    64    22   PCR-CTPP    No
  Zhou 2011            China (Asian)                  271    145                 112       14                  HB      289    159    117   13   TaqMan      Yes
  Custodio 2011        Brazil (Caucasian)             80     15                  31        34                  PB      100    67     4     29   PCR-RFLP    No
  Wang 2012            China (Asian)                  624    376                 218       30                  HB      580    355    205   20   PCR-RFLP    Yes
  Liu 2012             China (Asian)                  444    294                 105       45                  HB      442    334    89    19   MassARRAY   No
  Luo 2013             China (Asian)                  297    204                 63        30                  HB      415    297    96    22   MassARRAY   Yes
  Pan 2013             China (Asian)                  443    301                 116       27                  HB      443    327    101   15   MassARRAY   No
  Xu 2014              China (Asian)                  886    525                 301       60                  HB      886    540    311   35   PCR-RFLP    Yes
  Gao 2014             China (Asian)                  326    235                 73        18                  HB      376    279    84    13   MassARRAY   No
  Li 2014              China (Asian)                  368    183                 171       16                  HB      346    175    151   20   PCR-RFLP    Yes
  Fan 2016             China (Asian)                  115    31                  58        26                  HB      228    82     109   37   PCR-RFLP    Yes

PB, population-based; HB, hospital-based; Mixed, population and hospital based; HWE, Hardy Weinberg Equilibrium

Meta-analysis {#s2_2}
-------------

Table [2](#T2){ref-type="table"} demonstrates the results of overall and subgroup analyses. Overall, XRCC1 Arg194Trp polymorphism was significantly associated with increased risk of glioma under all five genetic models: the allele comparison, homozygote comparison, heterozygote comparison, recessive model, and dominant model \[for Trp vs. Arg: odds ratio (OR) and its 95% confidence interval (95%CI) = 1.18(1.05-1.34), *I*^2^= 73.96%; for TrpTrp vs. ArgArg: OR = 1.66(1.31-2.12), *I*^2^ = 45.84%, Figure [2](#F2){ref-type="fig"}; for ArgTrp vs. ArgArg: OR = 1.34(1.02-1.77), *I*^2^ = 91.01%; for TrpTrp vs. ArgArg+ArgTrp: OR = 1.47(1.26-1.72), *I*^2^ = 13.64%; TrpTrp+ArgTrp vs. ArgArg: OR = 1.17(1.01-1.35), *I*^2^ = 72.60%, respectively\].

###### Results of overall and subgroups analyses of pooled ORs and 95% CIs

                           No.   Trp vs. Arg        TrpTrp vs. ArgArg   ArgTrp vs. ArgArg   TrpTrp+ArgTrp vs. ArgArg   TrpTrp vs. ArgArg+ArgTrp                                                                                                               
  ------------------------ ----- ------------------ ------------------- ------------------- -------------------------- -------------------------- ------- ------------------ -------- ------- ------------------ -------- ------- ------------------ -------- -------
  **Overall**              16    1.18 (1.05-1.34)   0.01                73.96               1.66 (1.31-2.12)           0.04                       45.84   1.34 (1.02-1.77)   \<0.01   91.01   1.17 (1.01-1.35)   0.04     72.60   1.47 (1.26-1.72)   \<0.01   13.64
  **Ethnicity**                                                                                                                                                                                                                                               
  Asian                    11    1.20 (1.08-1.32)   \<0.01              47.86               1.52 (1.28-1.80)           0.13                       34.10   1.36 (0.97-1.91)   0.07     91.64   1.14 (1.05-1.24)   \<0.01   11.42   1.46 (1.24-1.72)   \<0.01   31.72
  Caucasian                5     1.15 (0.74-1.77)   0.54                89.03               1.93 (0.69-5.36)           0.21                       50.25   1.31 (0.77-2.23)   0.32     89.6    1.27 (0.76-2.12)   0.37     90.3    1.59 (0.95-2.67)   0.08     0
  **Source of controls**                                                                                                                                                                                                                                      
  Hospital                 11    1.19 (1.06-1.34)   \<0.01              57.30               1.69 (1.40-2.05)           0.41                       2.92    1.32 (0.91-1.91)   0.14     91.96   1.15 (1.02-1.30)   \<0.01   39.80   1.62 (1.34-1.95)   \<0.01   1.42
  Population               3     1.45 (0.63-3.35)   0.38                92.94               4.08 (2.11-7.90)           \<0.01                     40.26   2.58 (0.70-9.44)   0.15     94.3    1.88 (0.60-5.86)   0.28     94.4    1.79 (1.02-3.16)   0.04     0
  Mixed                    2     1.01 (0.90-1.14)   0.84                0                   1.05 (0.75-1.47)           0.79                       0       1.01 (0.87-1.16)   0.93     0       1.01 (0.88-1.16)   0.89     0       1.04 (0.75-1.44)   0.82     0
  **HWE**                                                                                                                                                                                                                                                     
  Yes                      11    1.05 (0.98-1.13)   0.13                16.78               1.34 (1.11-1.63)           0.36                       8.87    1.20 (0.86-1.68)   0.29     92.48   1.02 (0.94-1.11)   0.58     0       1.31 (1.09-1.58)   \<0.01   10.13
  No                       5     1.65 (1.23-2.22)   \<0.01              79.36               2.41 (1.79-3.65)           0.18                       35.78   1.79 (1.06-3.05)   0.03     87.21   1.81 (1.16-2.83)   0.01     85.86   1.93 (1.45-2.56)   \<0.01   0

Egger's test: 0.22; 0.83; 0.12; 0.06; 0.97

![Forest plot for overall analysis in TrpTrp vs. ArgArg comparison](oncotarget-08-21599-g002){#F2}

The cumulative meta-analysis accumulated the studies according to the publication year which displayed that the association change from non-significant to significant with new studies accumulated, and the CIs became increasing narrower (Figure [3](#F3){ref-type="fig"} and [Supplementary Figure 1](#SD1){ref-type="supplementary-material"} to Figure [4](#F4){ref-type="fig"}). Sensitivity analysis indicated that the overall analysis was not influenced by any single study (Figure [4](#F4){ref-type="fig"}).

![Forest plot for cumulative analysis in TrpTrp vs. ArgArg comparison](oncotarget-08-21599-g003){#F3}

![Forest analysis for sensitivity analysis in TrpTrp vs. ArgArg comparison](oncotarget-08-21599-g004){#F4}

In the subgroup analysis for ethnicity, no significant association was found in Caucasians under all five genetic models, but significantly increased risk was observed in Asians under for contrasts (Trp vs. Arg, TrpTrp vs. ArgArg, TrpTrp+ArgTrp vs. ArgArg, and TrpTrp vs. ArgArg+ArgTrp). After stratified analysis by source of controls, significant results were found both in hospital -based (Trp vs. Arg, TrpTrp vs. ArgArg, TrpTrp+ArgTrp vs. ArgArg, and TrpTrp vs. ArgArg+ArgTrp) and significant results for population-based controls (TrpTrp vs. ArgArg). Significant association existed in the studies conforming to HWE under two genetic models (TrpTrp vs. ArgArg and TrpTrp vs. ArgArg+ArgTrp) and in the studies deviating from HWE under all five genetic models.

Publication bias {#s2_3}
----------------

As shown in Figure [5](#F5){ref-type="fig"}, no obvious publication bias was found. The Egger's test also showed no evidence of publication bias (Trp vs. Arg: p = 0.22; TrpTrp vs. ArgArg: p= 0.83; ArgTrp vs. ArgArg: p = 0.12; TrpTrp+ArgTrp vs. ArgArg: p = 0.06; TrpTrp vs. ArgArg+ArgTrp: p = 0.97).

![Funnel plot for the assessment of publication bias in Trp vs. Arg comparison](oncotarget-08-21599-g005){#F5}

DISCUSSION {#s3}
==========

The first study on the association between XRCC1 Arg194Trp polymorphism and glioma risk was performed by Liu et al in 2007 \[[@R36]\], involving 756 cases and 754 controls from Chinese, and the results indicated no significant association between XRCC1 Arg194Trp polymorphisms and glioma risk. In 2012, Zhang et al conducted a meta-analysis to explore the role of XRCC1 Arg194Trp polymorphism in glioma risk based on 4 case-control studies \[[@R24], [@R27]--[@R29]\], and the results indicated that there was no remarkable association between them \[[@R8]\]. Then the findings from a meta-analysis by Sun et al. based on 7 studies were not totally similar to the above-mentioned results \[[@R7]\]. In 2013, Li et al. conducted a meta-analysis of 5 case-control studies, which revealed that XRCC1 Arg194Trp polymorphism might associated with risk of glioma \[[@R10]\]. The following meta-analysis performed by Jiang et al. of 6 case-control studies indicated Arg194Trp polymorphism might have no influence on the susceptibility of glioma \[[@R9]\]. The fifth meta-analysis from Zhang et al \[[@R11]\] including 8 case-controls showed that Arg194Trp polymorphism increased the glioma risk. The meta-analysis from He et al in 2014 based on 8 studies showed Arg194Trp probably increased risk for glioma due to studies deviating from HWE in controls \[[@R16]\]. Another six meta-analyses indicated that Arg194Trp polymorphisms might contribute to genetic susceptibility to glioma in the Chinese population \[[@R12], [@R14], [@R17]--[@R20]\]. Almost all published meta-analyses suggested that more large-scale, well-designed and population-based studies were required for further evaluation \[[@R7]--[@R19]\].

Obviously, their results are inconsistent ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). Nowadays, 16 case-control studies and have yielded inconsistent results (Figure [2](#F2){ref-type="fig"}). Meta-analysis is a useful tool to resolve the inconsistent results from single study, which has been broadly applied in epidemiological field \[[@R40]--[@R44]\]. Hence, we undertook this comprehensive meta-analysis to provide an updated approach on the overall relationship. The cumulative analysis was also used to evaluate the result influenced by sample sizes. In the end, our meta-analysis of 16 case-control studies indicated that XRCC1 Arg194Trp polymorphism probably was associated with increased risk of glioma, and the cumulative analysis suggested that the non-significant association would be change to significant if the sample sizes were enough. The subgroups analyses indicated that XRCC1 Arg194Trp polymorphism elevated disease risk in Asians, but not associated in Caucasians.

The results of our meta-analysis are opposed to the conclusions from previously six meta-analyses in overall population \[[@R7]--[@R10], [@R15], [@R16]\], which all indicated there was no association between XRCC1 Arg194Trp polymorphism and glioma risk. The major reason is that our meta-analysis included more studies than them; therefore, our meta-analysis is the most comprehensive one currently. In order to explore the influence of sample size on overall estimation, we conducted cumulative meta-analysis, which showed that the association became significant and the results were changed with the sample size cumulated (Figure [3](#F3){ref-type="fig"}). For the subgroup analysis, the results were varied; this might be also attributed to the sample sizes. Hence, relevant studies should be performed to further identify this relationship. Moreover, evidence indicates that ethnic-specific variation, different health care and socioeconomic class might exert an effect on the incidence of glioma \[[@R45]\]. When we performed subgroup analysis based on ethnicity, the results indicated no association in Caucasians but significant correlation in Asians, that might be attributable to the ethnic-specific background or insufficient sample size in Caucasians. Third, the results can be influenced by violations or deviations in HWE \[[@R46]\], which can explain the reason why the results were different of violation in HWE and deviation in HWE of our meta-analysis. Fourth, the source of controls also can impact the results. Generally, the population - based controls is more representative than hospital - based controls. In our meta-analysis, the result of hospital - based controls was different from that of population - based controls, and the former was similar with overall results whereas the latter was significant under two genetic models. This might indicate that the results of our meta-analysis were not influenced much by control source. Finally, the heterogeneity existed in the meta-analysis.

Our meta-analysis also is similar with the previous eight meta-analyses \[[@R7], [@R10], [@R11], [@R13], [@R17]--[@R20]\]. Therefore, our meta-analysis confirmed their results. We can observe that the association became significant from the study by Wang et al \[[@R32]\] in 2012 (Figure [3](#F3){ref-type="fig"}), which was just the sixth included study of meta-analysis by Jiang et al. \[[@R9]\]. The meta-analyses by Zhang et al. \[[@R11]\], He et al. \[[@R14], [@R16]\], Feng et al. \[[@R12]\], Xu et al. \[[@R13]\], Li et al. \[[@R17]\], Qi et al. \[[@R18]\] and Li et al. \[[@R19]\] also included this study and all of these meta-analyses showed a significant association except the one by He et al. \[[@R16]\]. This proved the evidence that the result could be influenced by sample size. Hence, the next advantage of meta-analysis is that we performed the cumulative meta-analysis.

Our meta-analysis also has its limitations. First, the primary studies only provided data regarding Caucasians and Asians; therefore, more studies involving other ethnicities such as African should be conducted to validate our results. Besides, the important information such as histological types should be improved in further studies. Second, other factors that might contribute to the heterogeneity, such as age, histological types, gender could not be explored due to the lack of relevant data were in original studies. Third, for lacking recommended quality assessment tool \[[@R44]\], it was difficult to assess the quality of included studies and its influence; these potential biases might result in lack of replication of definite conclusions. Fourth, although no publication bias was detected and we tried our best to identify relevant publications, due to the limitations of languages and using permission of databases, only studies published in English and Chinese were included. So several databases were not searched and the studies in other languages were omitted, which might result in the occurrence of selection bias. Finally, this meta-analysis merely detected the association between the XRCC1 Arg194Trp polymorphism and glioma based on crude data. Therefore, the effects of gene - gene and gene - environment interactions were not mentioned in this research.

In conclusion, the results of the present meta-analysis suggest that the XRCC1 Arg194Trp polymorphism is associated with increased risk of glioma, especially for Asians. Of course, the results of our meta-analysis should be treated with caution, but unlike previous meta-analyses, we do not need to emphasize that relevant studies should be carried out for enlarging the sample sizes.

MATERIALS AND METHODS {#s4}
=====================

This meta-analysis was reported following the recommended Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@R47]\].

Eligibility criteria {#s4_1}
--------------------

The study was included according to the following criteria: (1) the study assessed the association between the glioma and XRCC1 Arg194Trp polymorphism; (2) the study reported ORs and 95%CIs, or the number of individual genotypes in both case and control groups for their calculation; (3) the design was case-control or cohort study; and (4) the patients were microscopically diagnosed as glioma. In addition, if studies had the overlapping data, only the largest or the most complete one was included in the final analysis.

Search strategy {#s4_2}
---------------

The PubMed, Embase, CBM (chinese biomedical database), and CNKI (China National Knowledge Internet) databases were comprehensively searched up to August 13, 2016 (updated on December 22, 2016) using the following terms: (polymorphism OR mutation OR variant) AND (glioma OR "brain tumor" OR glioblastoma OR "glial cell tumors" OR "brain neoplasms") AND (XRCC1 OR "x-ray cross complementing group 1"). Additional studies were manually searched from the references of all identified studies and the recent reviews.

Data extraction {#s4_3}
---------------

Two authors selected studies according to the criteria listed above and extracted information from all eligible studies independently. The essential information contained the first author's name, year of publication, country of origin, ethnicity of subjects, source of control, genotyping method, number of cases and controls and genotype frequency, ORs and its 95%CIs, and HWE for controls. All disagreements were resolved by consulting with a third author.

Data analysis {#s4_4}
-------------

First, the heterogeneity among included studies was detected using *I*^2^ statistics \[[@R48]\]. The value of *I*^2^ ≤ 40% was considered no substantive heterogeneity existed, so the fixed effect model was employed; otherwise, the random-effects model was used \[[@R49]\]. The OR and 95% CI were calculated for estimating the association between XRCC1 Arg194Trp polymorphism and glioma under the following common used five genetic models \[[@R50]--[@R53]\]: allele comparison (Trp vs. Arg), homozygote comparison (TrpTrp vs. ArgArg), heterozygote comparison (ArgTrp vs. ArgArg), dominant model (TrpTrp+ArgTrp vs. ArgArg), and recessive model (TrpTrp vs. ArgArg+ArgTrp), respectively. The subgroups analyses based on the ethnicity, source of controls, and the HWE for controls were performed to explore the potential source of heterogeneity among studies. Sensitivity analysis was applied by excluding each single study each time to explore the stability of overall results. The cumulative meta-analysis was carried out to observe the change when with sample sizes were enlarged \[[@R22], [@R23]\]. The publication bias was detected by funnel plot analysis and the Egger linear regression test \[[@R54]\]. All the analyses were performed using the Comprehensive Meta-Analysis software, version 2.2 (Biostat, Englewood, New Jersey) \[[@R50], [@R52], [@R53]\] and all the *p* values were two-sided.
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